GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adverum Biotechnologies Inc (STU:AVU0) » Definitions » E10

Adverum Biotechnologies (STU:AVU0) E10 : €0.00 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Adverum Biotechnologies E10?

Note: As E10 is a main component used to calculate Shiller PE Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation sectione below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Adverum Biotechnologies's adjusted earnings per share data for the three months ended in Mar. 2024 was €0.000. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €0.00 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-06-09), Adverum Biotechnologies's current stock price is €13.40. Adverum Biotechnologies's E10 for the quarter that ended in Mar. 2024 was €0.00. Adverum Biotechnologies's Shiller PE Ratio of today is .


Adverum Biotechnologies E10 Historical Data

The historical data trend for Adverum Biotechnologies's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adverum Biotechnologies E10 Chart

Adverum Biotechnologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -16.02 -16.51

Adverum Biotechnologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.08 -16.13 -17.51 -16.51 -

Competitive Comparison of Adverum Biotechnologies's E10

For the Biotechnology subindustry, Adverum Biotechnologies's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adverum Biotechnologies's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adverum Biotechnologies's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Adverum Biotechnologies's Shiller PE Ratio falls into.



Adverum Biotechnologies E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Adverum Biotechnologies's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0/131.7762*131.7762
=0.000

Current CPI (Mar. 2024) = 131.7762.

Adverum Biotechnologies Quarterly Data

per share eps CPI Adj_EPS
201406 -2.949 100.560 -3.864
201409 -3.880 100.428 -5.091
201412 -3.704 99.070 -4.927
201503 -3.511 99.621 -4.644
201506 -3.386 100.684 -4.432
201509 -4.900 100.392 -6.432
201512 -5.003 99.792 -6.606
201603 -5.119 100.470 -6.714
201606 -15.664 101.688 -20.299
201609 -3.118 101.861 -4.034
201612 -5.119 101.863 -6.622
201703 -3.553 102.862 -4.552
201706 -2.403 103.349 -3.064
201709 -2.685 104.136 -3.398
201712 -2.704 104.011 -3.426
201803 -2.433 105.290 -3.045
201806 -2.568 106.317 -3.183
201809 -2.914 106.507 -3.605
201812 -2.110 105.998 -2.623
201903 -2.036 107.251 -2.502
201906 -2.036 108.070 -2.483
201909 -2.270 108.329 -2.761
201912 -2.700 108.420 -3.282
202003 -2.805 108.902 -3.394
202006 -3.197 108.767 -3.873
202009 -2.632 109.815 -3.158
202012 -3.206 109.897 -3.844
202103 -2.436 111.754 -2.872
202106 -3.735 114.631 -4.294
202109 -3.315 115.734 -3.774
202112 -3.098 117.630 -3.471
202203 -3.450 121.301 -3.748
202206 -4.162 125.017 -4.387
202209 -4.040 125.227 -4.251
202212 -3.115 125.222 -3.278
202303 -2.709 127.348 -2.803
202306 -2.861 128.729 -2.929
202309 -3.092 129.860 -3.138
202312 -2.109 129.419 -2.147
202403 0.000 131.776 0.000

Add all the adjusted EPS together and divide 10 will get our e10.


Adverum Biotechnologies  (STU:AVU0) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Adverum Biotechnologies E10 Related Terms

Thank you for viewing the detailed overview of Adverum Biotechnologies's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Adverum Biotechnologies (STU:AVU0) Business Description

Traded in Other Exchanges
Address
100 Cardinal Way, Redwood CIty, CA, USA, 94063
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

Adverum Biotechnologies (STU:AVU0) Headlines

No Headlines